Application No.: 10/554,026 Attorney Docket No.: O90951

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

1. (Currently amended): An apoptosis-inducing-agent composition, which contains a

protein that interacts with a FUSE binding protein as an active ingredient and at least one

pharmaceutical agent selected from an excipient, extending agent, binder, moistening agent,

disintegrating agent, lubricant, surfactant, dispersing agent, buffer agent, preservative.

solubilizing agent, antiseptic agent, flavoring agent, soothing agent, stabilizer, and isotonizing

agent.

2. (Currently amended): The apoptosis-inducing agent-composition according to claim

1, wherein the protein interacting with the FUSE binding protein is:

a protein consisting of the amino acid sequence represented by of SEO ID NO: 2 in the

sequence listing:

a protein consisting of an amino acid sequence derived from the amino acid sequence

represented by SEQ ID NO: 2 in the sequence listing by deletion, substitution, or addition of one

or several amino acids and having apoptosis-inducing activity; or

a partial peptide thereof having apoptosis-inducing activity.

Application No.: 10/554,026 Attorney Docket No.: O90951

3. (Withdrawn - amended): An apoptosis-inducing-agent composition, which contains a

polynucleotide encoding a protein that interacts with an FUSE binding protein as an active

ingredient.

4. (Withdrawn - amended): The apoptosis-inducing-agent composition according to

claim 3, wherein the polynucleotide encoding the protein that interacts with the FUSE binding

protein is: a polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1

in the sequence listing:

a polynucleotide hybridizing under stringent conditions to a polynucleotide consisting of

a nucleotide sequence complementary to the polynucleotide consisting of the nucleotide

sequence represented by SEQ ID NO: 1 in the sequence listing and encoding a protein having

apoptosis-inducing activity; or

a partial fragment thereof.

5. (Currently amended): The apoptosis-inducing-agent composition according to any

one of claims 1 to 4, which has a form that allows it to be introduced into a cell.

6. (Withdrawn - amended): The apoptosis-inducing agent composition according to

claim 5, wherein the form that allows introduction into a cell is a vector comprising a

polynucleotide sequence that expresses the protein that interacts with a FUSE binding protein as

an active ingredient.

Application No.: 10/554,026 Attorney Docket No.: O90951

7. (Currently amended): The apoptosis-inducing-agent composition according to claim

1, which is used for treating cancer.

8. (Withdrawn - currently amended): A method for inducing apoptosis, which is a

method for inducing apoptosis in a cell that proliferates due to the expression of a c-myc gene

and which comprises a step of causing the apoptosis-inducing agent composition according to

claim 1 to come into contact with the cell.

9. (Withdrawn): The method according to claim 8, wherein the cell is a cancer cell.

10. (Withdrawn): The method according to claim 8 or 9, wherein the cell is a cell within

a mammalian body.

11. (Withdrawn): The method according to claim 10, wherein the mammal is a human.

12. (Withdrawn): A method for treating cancer, wherein an effective dose of: a protein

consisting of the amino acid sequence represented by SEQ ID NO: 2 in the sequence listing; a

protein consisting of an amino acid sequence derived from the amino acid sequence represented

by SEQ ID NO: 2 in the sequence listing by deletion, substitution, or addition of 1 or several

amino acids and having apoptosis-inducing activity; or a partial peptide thereof is administered

to a mammal.

Application No.: 10/554,026 Attorney Docket No.: Q90951

13. (Withdrawn): A method for treating cancer, wherein an effective dose of: a

polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 in the

sequence listing; a polynucleotide hybridizing under stringent conditions to a polynucleotide

consisting of a nucleotide sequence complementary to the polynucleotide consisting of the

nucleotide sequence represented by SEQ ID NO: 1 in the sequence listing and encoding a protein

having apoptosis-inducing activity; or a fragment thereof is administered to a mammal.

14. (Withdrawn): The method according to claim 12 or 13, wherein the mammal is a

human.